Active malignancy modifies the association between temporary mechanical circulatory support and in-hospital mortality in high-risk percutaneous coronary intervention
Clicks: 1
ID: 323353
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #145 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Temporary mechanical circulatory support (tMCS) is frequently used during high-risk percutaneous coronary intervention (HR-PCI), yet outcomes in patients with active malignancy remain poorly characterised. Purpose To determine whether active malignancy modifies the association between tMCS use and in-hospital mortality in HR-PCI. Methods We performed a retrospective cohort study of PCI admissions in a large single-centre critical care database, the Medical Information Mart for Intensive Care IV (MIMIC-IV). HR-PCI was defined by early markers of haemodynamic instability or end-organ dysfunction within 48 hours of admission, including cardiogenic shock, vasopressor use, elevated lactate, acute kidney injury, or intensive care unit admission. Active malignancy was identified using diagnosis codes from the index hospitalisation, excluding non-melanoma skin cancers. Multivariable logistic regression with cluster-robust standard errors assessed in-hospital mortality, including an interaction term between malignancy and tMCS use. Adjusted predicted mortality was estimated across malignancy and tMCS strata. Results Among 2,867 HR-PCI admissions, 163 (5.7%) had active malignancy and 172 (6.0%) received tMCS. Active malignancy significantly modified the association between tMCS use and mortality (interaction OR 13.4, 95% CI 2.0–91.4; p=0.008). Model-predicted mortality was low among patients without malignancy regardless of tMCS use (0.8% without tMCS vs 0.9% with tMCS) and modest among patients with malignancy not receiving tMCS (1.5%), but markedly higher among those with both malignancy and tMCS (17.6%). Although the confidence interval for this subgroup was wide owing to small numbers of patients with malignancy receiving tMCS, the interaction remained statistically significant, supporting consistent effect modification rather than imprecision alone. Conclusion In HR-PCI, active malignancy identifies a distinct high-risk phenotype in which tMCS use is associated with substantially higher in-hospital mortality, highlighting the need for malignancy-informed risk stratification and prospective studies to guide mechanical support decision-making in patients with active cancer.Figure 1
| Reference Key |
openalex_W7172347334
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | S Govindji, A Diab |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.173
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.